Treatment of ischemic events

Abstract

The invention relates to the treatment of an ischemic event such as a stroke or myocardial infarction. The invention provides a method for modulating an ischemic event in a subject comprising providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides use of an NF-κB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of reperfusion injury occurring after an ischemic event in a subject.

What is claimed is:  
     
         1 . A method for modulating an ischemic event in a subject, said method comprising: 
 providing the subject with a gene-regulatory peptide or functional analogue thereof.    
     
     
         2 . The method according to  claim 1  wherein said gene-regulatory peptide or functional analogue thereof down-regulates translocation, activity, or translocation and activity of a gene transcription factor.  
     
     
         3 . The method according to  claim 2  wherein said gene transcription factor comprises an NF-kappaB/Rel protein.  
     
     
         4 . The method according to  claim 3  wherein translocation, activity, or translocation and activity of said NF-kappaB/Rel protein is inhibited.  
     
     
         5 . The method according to  claim 1  wherein said gene-regulatory peptide or functional analogue thereof has NFkappaB down-regulating activity in LPS stimulated RAW264.7 cells.  
     
     
         6 . The method according to  claim 2  wherein said gene-regulatory peptide or functional analogue thereof has NFkappaB down-regulating activity in LPS stimulated RAW264.7 cells.  
     
     
         7 . The method according to  claim 3  wherein said gene-regulatory peptide or functional analogue thereof has NFkappaB down-regulating activity in LPS stimulated RAW264.7 cells.  
     
     
         8 . The method according to  claim 4  wherein said gene-regulatory peptide or functional analogue thereof has NFkappaB down-regulating activity in LPS stimulated RAW264.7 cells.  
     
     
         9 . The method according to  claim 1  wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.  
     
     
         10 . The method according to  claim 2  wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.  
     
     
         11 . The method according to  claim 3  wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.  
     
     
         12 . The method according to  claim 4  wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.  
     
     
         13 . The method according to  claim 5  wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.  
     
     
         14 . The method according to  claim 6  wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.  
     
     
         15 . The method according to  claim 7  wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.  
     
     
         16 . The method according to  claim 8  wherein the subject is at risk of experiencing reperfusion injury after said ischemic event.  
     
     
         17 . The method according to any one of claims  1  through  16  wherein said gene-regulatory peptide or functional analogue thereof has NFkappaB down-regulating activity in LPS unstimulated RAW264.7 cells.  
     
     
         18 . The method according to  claim 1  further comprising: 
 also providing the subject with a therapeutic amount of a thrombolytic agent.  
 
     
     
         19 . The method according to  claim 8  wherein the thrombolytic agent has tissue plasminogen activity.  
     
     
         20 . A method for treating an ischemic event in a subject, said method comprising: 
 inhibiting, in the subject, a gene transcription factor comprising NF-kappaB/Rel protein by providing the subject with a gene-regulatory peptide so as to down-regulate translocation, activity, or translocation and activity of the gene transcription factor, thus treating the subject's ischemic event.